SOURCE: Oryzon Genomics


May 18, 2016 08:00 ET

ORYZON to Extend Its R&D Collaborationon ORY-1001 Until March 2017

BARCELONA, SPAIN and CAMBRIDGE, MA--(Marketwired - May 18, 2016) -  Oryzon Genomics (ISIN Code: ES0167733015), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced today that the 2-year R&D collaboration with Roche concerning ORY-1001, licensed to Roche in 2014, has been extended until March 2017.

ORY-1001 (RG6016) is a highly potent and selective inhibitor of LSD1 currently in Phase I/IIA in acute leukemia patients. The license agreement by which the development and commercial rights to ORY-1001 were granted to Roche, included a 2-year collaborative research program between Oryzon and Roche to further explore the potential of ORY-1001 in oncology and haematology. The program has delivered additional insight into the drug's mechanism of action, provided support for its use in indications beyond acute leukemia and has expanded the toolbox for future and current clinical trials. Oryzon will continue to support the development of ORY-1001 through an extension of the collaborative research program that will run until March 2017 with the main goal to finalize the transfer of the newly generated technology and knowledge.

Carlos Buesa, Oryzon's CEO, has declared: "This collaboration between Roche and Oryzon has been highly satisfactory and the success of the collaboration is reflected in four newly filed patent applications. We have been impressed by the experience of our partner and are convinced the results generated will strengthen the further clinical development of ORY-1001."

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon's LSD1 program is currently covered by 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit


This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates" and similar expressions.

Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public.

Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A, have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information